Adamas Pharmaceuticals Priced, Nasdaq: ADMS
Developing improved formulations of existing drugs for CNS disorders.
Industry: Health Care
First Day Return: -12.4%
Industry: Health Care
ADMS
Developing improved formulations of existing drugs for CNS disorders.
| IPO Data | |
|---|---|
| IPO File Date | 03/05/2014 |
| Offer Price | $16.00 |
| Price Range $16.00 - $18.00 | |
| Offer Shares (mm) | 3.0 |
| Deal Size ($mm) | $48 |
| Lock-Up Date | IPO Pro Only |
| Street Research | IPO Pro Only |
| IPO Data | |
|---|---|
| IPO Date | 04/09/2014 |
| Offer Price | IPO Intelligence Only |
| Price Range | IPO Intelligence Only |
| Offer Shares (mm) | IPO Intelligence Only |
| Deal Size ($mm) | $48 |
| Lock-Up Date | IPO Intelligence Only |
| Street Research | IPO Intelligence Only |
| Underwriters |
|---|
| IPO Intelligence Only |
| Company Data | |
|---|---|
| Headquarters | Emeryville, CA, United States |
| Founded | 2000 |
| Employees at IPO | 22 |
| Website www.adamaspharma.com | |
IPO News for Adamas Pharmaceuticals
Adamas Pharmaceuticals (ADMS) Performance
